Mechanism of glucose-6-phosphate dehydrogenase-mediated regulation of coronary artery contractility

Ata H, Rawat DK, Lincoln T, Gupte SA. Mechanism of glucose-6-phosphate dehydrogenase-mediated regulation of coronary artery contractility. Am J Physiol Heart Circ Physiol 300: H2054-H2063, 2011. First published March 11, 2011; doi: 10.1152/ajpheart.01155.2010.-We previously identified glucose-6-phosphate dehydrogenase (G6PD) as a regulator of vascular smooth muscle contraction. In this study, we tested our hypothesis that G6PD activated by KCl via a phosphatase and tensin homologue deleted on chromosome 10 (PTEN)-protein kinase C (PKC) pathway increases vascular smooth muscle contraction and that inhibition of G6PD relaxes smooth muscle by decreasing intracellular Ca2+ ([Ca2+](i)) and Ca2+ sensitivity to the myofilament. Here we show that G6PD is activated by membrane depolarization via PKC and PTEN pathway and that G6PD inhibition decreases intracellular free calcium ([Ca2+](i)) in vascular smooth muscle cells and thus arterial contractility. In bovine coronary artery (CA), KCl (30 mmol/l) increased PKC activity and doubled G6PD V-max without affecting K-m. KCl-induced PKC and G6PD activation was inhibited by bisperoxo(pyridine-2-carboxyl) oxovanadate (Bpv; 10 mu mol/l), a PTEN inhibitor, which also inhibited (P < 0.05) KCl-induced CA contraction. The G6PD blockers 6-aminonicotinamide (6AN; 1 mmol/l) and epiandrosterone (EPI; 100 mu mol/l) inhibited KCl-induced increases in G6PD activity, [Ca2+](i), Ca2+-dependent myosin light chain (MLC) phosphorylation, and contraction. Relaxation of precontracted CA by 6AN and EPI was not blocked by calnoxin (10 mu mol/l), a plasma membrane Ca2+ ATPase inhibitor or by lowering extracellular Na+, which inhibits the Na+/Ca2+ exchanger (NCX), but cyclopiazonic acid (200 mu mol/l), a sarcoplasmic reticulum Ca2+ ATPase inhibitor, reduced (P < 0.05) 6AN- and EPI-induced relaxation. 6AN also attenuated phosphorylation of myosin phosphatase target subunit 1 (MYPT1) at Ser855, a site phosphorylated by Rho kinase, inhibition of which reduced (P < 0.05) KCl-induced CA contraction and 6AN-induced relaxation. By contrast, 6AN increased (P < 0.05) vasodilator-stimulated phosphoprotein (VASP) phosphorylation at Ser239, indicating that inhibition of G6PD increases PKA or PKG activity. Inhibition of PKG by RT-8-Br-PET-cGMPs (100 nmol/l) diminished 6AN-evoked VASP phosphorylation (P < 0.05), but RT-8-Br-PET-cGMPs increased 6AN-induced relaxation. These findings suggest G6PD inhibition relaxes CA by decreasing Ca2+ influx, increasing Ca2+ sequestration, and inhibiting Rho kinase but not by increasing Ca2+ extrusion or activating PKG.